28 results about "HCG - Human chorionic gonadotropin" patented technology

A composition of matter includes an antisense phosphorodiamidate morpholino oligomer (MO) that includes an MO base sequence. The MO base sequence is arranged to bind a corresponding complementary base sequence of messenger RNA (mRNA) transcribed from one or more genes for the beta subunit of human chorionic gonadotropin (hCG-β). An inventive method, for suppressing intracellular synthesis of a beta subunit of human chorionic gonadotropin (hCG-β), includes introducing such an MO into one or more cells.

The present disclosure relates to a chemiluminescence analyzer, comprising: a sample preparation device configured to pre-dilute a blood sample under test by using a diluent, and mix the pre-diluted blood sample under test and a reaction reagent in a reaction vessel to obtain a sample liquid under test; a substrate providing device configured to provide a luminescent substrate into the reaction vessel containing the sample liquid under test so as to carry out a chemiluminescence reaction; a photometric device, at least comprising a photometer; and a data processing device configured to obtain a test result of human chorionic gonadotropin (HCG) in the blood sample under test on the basis of a luminescent signal and a preset calibration model. A first linear test range of the photometer is [A1, A2] photon count / second, and in the first linear test range, the intensity of the luminescent signal generated in the chemiluminescence reaction is linearly related to the photon count output by the photometer, wherein A1 is less than or equal to 2000 and A2 is greater than or equal to 108. Therefore, the testing efficiency and accuracy of HCG can be improved without increasing the costs.

The present invention discloses a human chorionic gonadotropin (HCG) content detection system, comprising: an extreme feedback module internally provided with a color development acceleration device for accelerating the color development of a test strip until the color development area displays the extreme color; a first acquisition module for collecting test strip images of each test strip displaying the extreme color; a difference calculation module for acquiring the RGB data of each pixel in the first color development area and establishing a difference function; a second acquisition module for collecting real-time images of each test strip; a model training module for using the labeled real-time image as input and the first color development area as output, retraining the initial model to obtain a feature labeling model; a content output module for inputting the unlabeled real-time image into the feature labeling model to obtain a feature display area, adjusting the content detection model according to the difference function to obtain an optimized detection model, and inputting the RGB data of each pixel in the feature display area into the optimized detection model to obtain the hormone content. The present invention improves the accuracy of human chorionic gonadotropin content detection.

The present invention provides an immunosensor using a carbon dot composite as a probe and a coreactant, and a preparation method and an application thereof. By using dSiO₂ nanospheres with a large surface area to load a large amount of CDs, a CDs@dSiO₂ nanosphere composite material is prepared as a coreaction reagent for Ru(bpy)₃²⁺, so that the Ru(bpy)₃²⁺-CDs@dSiO₂ system has a significant enhancement in electrochemiluminescence. The present invention constructs an electrochemiluminescence immunosensor based on a carbon dot composite as a Ru(bpy)₃²⁺ coreactant and as a nanoprobe for immobilizing a secondary antibody, for the sensitive detection of human chorionic gonadotropin (HCG). The sensor has the characteristics of high sensitivity, strong specificity, good stability, low detection limit, wide linear range, and simple operation.

The invention relates to a marker for detecting and / or diagnosing 21-trisomy syndrome, 18-trisomy syndrome and neural tube defects and application of the marker, and belongs to the technical field of medical detection. The marker provided by the invention is selected from one or more of maternal serum D-dimer (D-D), pregnancy related plasma protein A (PAPP-A) and free human chorionic gonadotropin beta subunit (Free beta-hCG). The D-D + PAPP-A + Free beta-hCG model provided by the invention has the highest diagnostic value for 21-trisomy syndrome (DS) and 18-trisomy syndrome (ES), and the combination of D-D and PAPP-A and / or Free beta-hCG can improve the diagnostic value, diagnostic sensitivity and screening effect for neural tube defects (NTD). A new marker and a screening scheme are provided for simultaneously monitoring and diagnosing DS, ES or NTD fetuses of early pregnancy pregnant women in the clinical early stage.

It relates to sustained release formulations of human chorionic gonadotropin (hCG). The present disclosure relates to sustained release dosage forms of human chorionic gonadotropin (hCG) or derivatives or isoforms thereof. The sustained release hCG dosage forms include biodegradable polymer microspheres that provide sustained release of hCG over a desired period of time.

This provides a means to continuously, concisely, and objectively visualize the trends in measurement results. [Solution] An in vitro diagnostic test kit for determining information on human chorionic gonadotropin contained in the urine of a subject in multiple stages, comprising one or more detectors equipped with a capture member that specifically binds to human chorionic gonadotropin upon contact with a sample, wherein one or more visual indicator parts provided on the detector itself exhibit multiple visual states that can be identified by at least one of position, hue, intensity, or number of appearances upon reaction with urine, and the visual states or combinations thereof are associated with multiple judgment criteria corresponding to human chorionic gonadotropin.

A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.

The invention relates to a test cartridge for use in an analysis unit for hormone measurement, comprising at least one insertion opening for receiving a sample to be measured, in particular saliva, urine, or blood, and at least one reagent reservoir, wherein reaction reagents, in particular comprising at least one buffer medium, are stored in the at least one reagent reservoir, further comprising measuring chambers, wherein in each measuring chamber, preferably exclusively for one menstrual cycle hormone, detection reagents for the quantitative and / or qualitative detection of menstrual cycle hormones are stored, and at least one fluid path, wherein the fluid path is configured as a connection between the insertion opening and the measuring chambers and / or the reagent reservoir and the measuring chambers, wherein measuring chambers with detection reagents for three, in particular at least five, menstrual cycle hormones,preferably including at least progesterone and / or estrogen and / or follicle-stimulating hormone and / or luteinizing hormone and / or human chorionic gonadotropin.

A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.

The present invention provides the use of human chorionic gonadotropin (HCG) in the preparation of a drug for repairing ovarian damage in tilapia, belonging to the field of aquaculture technology. The present invention provides the use of human chorionic gonadotropin in the preparation of a drug for repairing ovarian damage in tilapia. Human chorionic gonadotropin can increase the content of hormones and vitellogenin in serum and increase the expression of sex hormone-related genes in the ovary. At the same time, one or more of estradiol, human chorionic gonadotropin, luteinizing hormone-releasing hormone and coumestrol can increase the body weight of tilapia exposed to copper and cadmium contaminated water phase, providing a new idea for the preparation of new growth-promoting drugs.

The invention aims to provide a superovulation inducing method for rats. According to the present invention, it is possible to provide a method for inducing superovulation, characterized in that an anti-statin antibody and a horse chorionic gonadotropin (eCG) are simultaneously administered to a female rat less than 6 weeks old, followed by a human chorionic gonadotropin (hCG). In addition, according to the present invention, an in vitro fertilization method using an ovum produced by the method of the present invention can be provided. The method can be used for rats of various strains.

The present application relates to the technical field of pregnancy test kits, and in particular to an electronic early pregnancy test kit. The present application provides an electronic early pregnancy test kit, comprising a reagent strip, a spectral analysis system, a temperature sensor, a processor, and a display unit. First, an LED light source is used for illuminating the reagent strip, and reflected light is received by means of a corresponding photosensitive sensor; then the temperature sensor is used for monitoring the temperature of the reagent strip in real time, and the processor compensates and corrects a photosensitive signal on the basis of temperature data, and calculates the level of human chorionic gonadotropin by analyzing corrected spectral data; and finally, the gestational age is estimated on the basis of a calculation result and is presented on the display unit, thereby not only improving the accuracy and reliability of test, but also achieving active compensation for environmental factors, while providing a quantitative result and accurate gestational age estimation by means of spectral analysis.

This invention relates to aptamers having selectivity and / or specificity for human chorionic gonadotropin (hCG). Also provided for are a biosensor comprising the aptamers having selectivity and / or specificity for hCG and a method for detecting human chorionic gonadotropin (hCG) in a sample using the aptamers or biosensor of the invention, comprising detecting binding of the aptamers to hCG. The invention also relates to a method of identifying aptamers, from a candidate mixture of nucleic acids, that bind to a distinct site of a target molecule, as opposed to another site on the target molecule.

The invention belongs to the field of veterinary drugs, and discloses a novel veterinary drug for promoting ovulation and pregnancy rate of female livestock and a preparation method thereof. The veterinary drug is prepared from gonadorelin, human chorionic gonadotropin, pregnant mare serum gonadotropin, vitamin A palmitate, vitamin E acetate, sodium selenite, zinc sulfate heptahydrate, herba epimedii powder, radix angelicae sinensis powder and corn starch. The preparation method comprises the key steps of performing cryogenic crushing on the composite traditional Chinese medicine powder, adding the fat-soluble vitamins through melt spraying, performing gradient mixing on hormones, performing vibrated fluidized bed drying and the like. Through the synergistic effect of hormones, vitamins, trace elements and traditional Chinese medicines, the problems of single ovulation promoting effect, limited pregnancy rate improvement and poor preparation stability in the prior art are effectively solved. Tests prove that the veterinary drug can remarkably improve the ovulation rate and pregnancy rate of cows, sows and ewes, and the veterinary drug is good in product uniformity, high in stability and convenient to use and has good clinical application prospects.

Provided is a test strip for detecting human chorionic gonadotropin (HCG) in saliva and a preparation method thereof, and belongs to the technical field of test strip detection. each 100 mL of the sample pad treatment solution includes the following components: 1.0 g to 1.5 g of Tris, 0.3 g to 0.8g of casein, 50 µL to 100 µL of Tween-20, 0.5 g to 1.5 g of NaCl, 0.15 g to 0.2 g of dodecyltrimethylammonium bromide (DTAB), 0.8 g to 1.2 g of 4-nonylphenyl-polyethylene glycol, 3.5 g to 4.0 g of borax, 0.5 g to 1 g of polyvinylpyrrolidone (PVP), 3 g to 5 g of dithiothreitol (DTT), and 0.8 g to 2 g of L-cysteine. The test strip shows a high sensitivity and a desirable stability, can be stored at a room temperature for a long time and not affected by the time and place of sample collection.

1. Name of the Design Product: Packaging Box (Human Chorionic Gonadotropin Test Strip). 2. Use of the Design Product: For product packaging. 3. Design Key Points of the Design Product: The combination of shape and pattern. 4. Picture or Photograph that Best Illustrates the Design Key Points: Perspective view.

The invention relates to the field of medical detection, and discloses a kit and a method for detecting human chorionic gonadotropin, the kit comprises a ruthenium complex labeled human chorionic gonadotropin detection antibody, a magnetic microsphere coated by a human chorionic gonadotropin capture antibody, and a diluent; the diluent comprises a bis (2-hydroxyethyl) amino (trihydroxymethyl) methane buffer agent, chloride, bovine serum albumin, gelatin and a surfactant. The method comprises the following steps: mixing a ruthenium complex-labeled human chorionic gonadotropin detection antibody defined in the kit, magnetic microspheres coated with a human chorionic gonadotropin capture antibody, a diluent and a detection sample for reaction; and sucking the obtained reaction liquid into an electrochemical reaction tank to carry out electrochemical luminescence reaction. The method and the kit are high in sensitivity, good in repeatability, wide in linear range and strong in anti-interference capability, detection time can be shortened, and wide application can be realized.

The invention relates to a test cartridge for use in an analysis unit for hormone measurement, having: at least one insertion opening for receiving a sample to be measured, in particular saliva or urine or blood, and at least one reagent store, wherein reaction reagents, in particular comprising at least one buffer medium, are stored in the at least one reagent store; measurement chambers, wherein in each measurement chamber, preferably exclusively for a menstruation cycle hormone, detection reagents for the quantitative and / or qualitative detection of menstruation cycle hormones are stored; and at least one fluid path, wherein the fluid path is formed as a connection between the insertion opening and the measurement chambers and / or the reagent store and the measurement chambers, wherein measurement chambers with detection reagents for three, in particular at least five, menstruation cycle hormones, preferably at least for progesterone and / or oestrogen and / or follicle-stimulating hormone and / or luteinising hormone and / or human chorionic gonadotropin, are comprised.

To provide modified TFF2 polypeptides.SOLUTION: Described herein are modified TFF2 polypeptides, compositions comprising these polypeptides, and their use to treat cancer and inflammation. In some embodiments, the improved properties of the disclosed modified TFF2 polypeptides are achieved using chemical modifications including PEGylation or poly (D,L-lactic-co-glycolic acid) (PLGA), and / or polysialylation (PSA), and / or fusion proteins, including fusion proteins with C-terminal peptide (CTP) of human chorionic gonadotropin β subunit, PASylation, homo-amino acid polymers (HAP), elastin-like peptides (ELPylation), XTENylated, and combinations of these modifications.SELECTED DRAWING: None

The application discloses an antibody against human chorionic gonadotropin and application thereof, and relates to the field of antibodies. The antibody against human chorionic gonadotropin disclosed by the application comprises a heavy chain complementarity determining region and a light chain complementarity determining region, the antibody provides an important raw material source for detection of human chorionic gonadotropin, and has good affinity or activity.

The invention discloses a fish gonadotropin II in-vivo expression vector as well as a construction method and application thereof, and belongs to the technical field of bioengineering. The fish gonadotropin II in-vivo expression vector is constructed by adopting a primer bridging method and specifically comprises the following steps: connecting a beta subunit and an alpha subunit of epinephelus coioides gonadotropin II to the carboxyl terminal of human chorionic gonadotropin to form a GTHII beta-CTP-alpha target base sequence fragment in a single-chain form; and the target base sequence fragment of the GTHII beta-CTP-alpha is inserted into a multiple cloning site of a pcDNA3.1 / Zeo (+) no-load plasmid. The method has the beneficial effects that in-vivo expression of the gonadotropin II gene of the fish is realized, early ovarian development of the fish can be induced, injection is performed once every 10 days and only needs to be performed three times, the injection times are reduced, the workload is reduced, the cost is reduced, and more importantly, the ovarian development induction efficiency is improved to about 95%.

The present application adopts human chorionic gonadotropin and indocyanine green-succinimidyl ester to carry out coupling reaction, and provides an ovarian follicle near-infrared fluorescent probe, and the preparation method of the probe is as follows: indocyanine green-succinimidyl ester solution and human chorionic gonadotropin solution are added into phosphate buffer solution with pH of 7.4-7.5 according to a proper ratio to obtain a mixed solution, stirring is carried out to react, and then the product is purified. The ovarian follicle near-infrared fluorescent probe provided by the present application has the advantages of rich raw material source, low cost, high clinical transformation and application value compared with the prior art, and has the characteristics of strong specificity, good light stability, deep penetration, high spatial resolution, fast biological metabolic rate, stable observation time window, no toxic side effects, and the like. The preparation method of the probe is simple in operation, good in stability and repeatability. The present application further provides an ovarian follicle contrast agent containing the ovarian follicle near-infrared fluorescent probe, and the contrast agent has high targeting, strong contrast, no toxic side effects and fast biological metabolic rate.

The application relates to the technical field of pregnancy test sticks, in particular to an electronic early pregnancy detection stick. The application provides an electronic early pregnancy detection stick which comprises a reagent strip, a spectrum analysis system, a temperature sensor, a processor and a display unit. First, the reagent strip is irradiated by using an LED light source, and reflected light is received by a corresponding photosensitive sensor; then the temperature of the reagent strip is monitored in real time by using the temperature sensor, the photosensitive signal is compensated and corrected based on temperature data by the processor, and the human chorionic gonadotropin level is calculated by analyzing the corrected spectrum data; finally, the gestational age is estimated based on the calculation result and presented on the display unit; not only the accuracy and reliability of detection are improved, but also active compensation of environmental factors is realized, and quantitative results and accurate gestational age estimation are provided by spectrum analysis.

The invention provides a method for purifying recombinant human chorionic gonadotropin (rhCG), and particularly relates to a method for realizing high-quality purification of the recombinant human chorionic gonadotropin (rhCG) by pretreating cell sap through a flocculating agent poly (diallyldimethylammonium chloride) (pDADMAC) and matching with dye affinity chromatography and cation exchange chromatography. The yield of the rhCG prepared by the purification method is more than 98%, the purity reaches 99.9%, the purified liquid hardly contains dissociation subunits, and the content of process impurities is low.

The invention provides optimized upstream processes for the production of recombinant gonadotropins including corifollitropin alfa (CFA), recombinant human chorionic gonadotropin (r-hCG), and recombinant human follicle- stimulating hormone (r-hFSH) in mammalian cell culture. The processes comprise revival of CHO cells from cryopreservation, expansion in shake flasks, seed generation in wave bioreactors, and production in stirred-tank bioreactors operated in fed-batch mode. Defined media supplemented with additives such as N-acetyl mannosamine, or stabilized glutamine enhance cell viability, productivity, and glycosylation quality. Cultures are terminated at defined viability thresholds or timepoints, and clarified by sequential depth and membrane filtration. The methods offer scalability, reproducibility, and superior product quality compared to conventional approaches, enabling consistent large-scale manufacture of therapeutic gonadotropins for fertility treatments and hormone therapies.

The present invention relates to a chemiluminescence analyzer, which comprises: a sample preparation device, which is used for pre-diluting a to-be-detected blood sample by using a diluent, and mixing the pre-diluted to-be-detected blood sample with a reaction reagent in a reaction container to obtain a to-be-detected sample liquid; the substrate providing device is used for providing a luminous substrate into the reaction container filled with a sample solution to be detected so as to carry out a chemiluminescence reaction; the light measuring device at least comprises a photometer; and the data processing device is used for obtaining a detection result of the human chorionic gonadotropin in the blood sample to be detected according to the light-emitting signal and a preset calibration model. The first linear detection range of the photometer is [A1, A2] photon counting / second, in the first linear detection range, the intensity of a light-emitting signal generated in the chemiluminescence reaction and the photon counting output by the photometer are in a linear relation, A1 is smaller than or equal to 2000, and A2 is larger than or equal to 108. Therefore, the HCG detection efficiency and accuracy can be improved under the condition that the cost is not increased.